Rua Bioscience Limited — Earnings Release 2023

Mar 1, 2023

Template Results announcement

==> picture [101 x 49] intentionally omitted <==

(for Equity Security issuer/Equity and Debt Security issuer)

Updated as at 17 October 2019

Results for announcement to the market	Results for announcement to the market	Results for announcement to the market	Results for announcement to the market
Name of issuer	Rua Bioscience Limited
Reporting Period	6 months to December 2022
Previous Reporting Period	6 months to December 2021
Currency	NZD
Amount (000s)		Percentage change
Revenue from continuing operations	$ 254	-29%
Total Revenue	$ 254	-29 %
Net profit/(loss) from continuing operations	$ 719	+129%
Total net profit/(loss)	$ 719	+129 %
Interim/Final Dividend
Amount per Quoted Equity Security	N/A
Imputed amount per Quoted Equity Security	N/A
Record Date	N/A
Dividend Payment Date	N/A
	Current period		Prior comparable period
Net tangible assets per Quoted Equity Security	$0.07		$0.16
A brief explanation of any of the figures above necessary to enable the figures to be understood
Authority for this announcement
Name of person authorised to make this announcement	Hamish White, Chief Financial Officer
Contact person for this announcement	Kerry Donovan, Communications and Corporate Affairs Manager
Contact phone number	021 128 7689
Contact email address	info@ruabio.com
Date of release through MAP	01/03/2023